2,2-diacetoxy-propane | 32786-47-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-diacetoxy-propane
• 英文别名: 2,2-Diacetoxy-propan；2,2-Diacetoxypropane；2-acetyloxypropan-2-yl acetate
• CAS: 32786-47-3
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: KTCCOCRJFOKLPW-UHFFFAOYSA-N

物化性质

• 沸点：
  49.5-50 °C(Press: 7 Torr)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(3,5,5-三甲基-1,2,4-三四氢呋喃-3-基)乙酮 以2%的产率得到
  参考文献：
  名称：

  GRIESBAUM, KARL;GREUNIG, HANS-JOACHIM;VOLPP, WILLI;JUNG, IN-CHAN, CHEM. BER., 124,(1991) N, C. 947-956

  摘要：

  DOI：

文献信息

• GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY
  申请人：Rafai Far Adel

  公开号：US20120149632A1

  公开（公告）日：2012-06-14

  The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections.

  这项发明涉及具有与母体糖肽或脂质糖肽抗生素相比具有改变的电离状态的糖肽和脂质糖肽抗生素衍生物，并且具有在生理条件下能够再生为母体糖肽或脂质糖肽抗生素的能力。这些化合物可用作预防和/或治疗细菌感染的抗生素。
• Method for the preparation of 6alpha-fluoro corticosteroids
  申请人：——

  公开号：US20030162959A1

  公开（公告）日：2003-08-28

  A method for producing a 6&agr;-fluorinated corticosteroid or derivative thereof by reacting a 17-hydroxy-21-ester epoxide of Formula II 1 with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6&agr;-fluorinated compound of Formula VII 2 R 1 can be OC(O)—R d ; R 4 can be C(O)—R d ; R 3 can be H or R d . Each R d may be the same or different and is independently selected from (C 1-4 )alkyl, aryl and heteroaryl. The dashed line can be a single or a double bond. R 4 may be, for example, acetyl; R 3 may be, for example, alpha or beta methyl; R 4 may be, for example, acetate or propionate. The stereoselective fluorinating agent used in the reaction may be, for example, a fluoropyridinium or fluoroquinuclidium compound, for example, Selectfluor®.

  通过将式II1的17-羟基-21-酯环氧化合物与具有立体选择性的氟化剂反应，以立体选择性形成式VII2的21-酯-17-羟基6α-氟化合物的方法，其中R1可以是OC(O)—Rd；R4可以是C(O)—Rd；R3可以是H或Rd。每个Rd可以相同也可以不同，并且从(C1-4)烷基、芳基和杂环芳基中独立选择。虚线可以是单键或双键。例如，R4可以是乙酰基；例如，R3可以是α或β甲基；例如，R4可以是乙酸酯或丙酸酯。反应中使用的具有立体选择性的氟化剂可以是氟吡啶或氟喹啉化合物，例如Selectfluor®。
• N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE
  申请人：Suetsugu Satoshi

  公开号：US20120122773A1

  公开（公告）日：2012-05-17

  The present invention provides a compound of formula (I): wherein R 1a is optionally substituted C 1-6 alkyl, etc.; R 1m is hydrogen atom, etc.; G 1 , G 2 , G 3 and G 4 are (i), etc. ((i) G 1 is —N(R 1b )—, G 2 is —CO—, G 3 is —C(R 1c )(R 1d )—, and G 4 is oxygen, etc.); R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are each independently optionally substituted C 1-6 alkyl, etc.; R 2 is optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3c and R 3d are each independently a group: -A-B (A is a single bond, etc., B is hydrogen atom, etc.), etc.; n is 1, etc.; R 5 is C 1-4 alkoxycarbonyl, etc., or a pharmaceutically acceptable salt thereof, which is useful as a renin inhibitor.

  本发明提供了一种化合物，其化学式为(I)：其中R1a是可选取代的C1-6烷基等；R1m是氢原子等；G1，G2，G3和G4是(i)等，((i) G1是—N(R1b)—，G2是—CO—，G3是—C(R1c)(R1d)—，G4是氧原子等)；R1b是可选取代的C1-6烷基等；R1c和R1d分别独立地是可选取代的C1-6烷基等；R2是可选取代的C1-6烷基等；R3a、R3b、R3c和R3d分别独立地是一种基团：-A-B（其中A是单键等，B是氢原子等）等；n是1等；R5是C1-4烷氧羰基等，或其药学上可接受的盐，其作为一种肾素抑制剂是有用的。
• PHENYLMORPHOLINES AND ANALOGUES THEREOF
  申请人：Blough Bruce E.

  公开号：US20130203752A1

  公开（公告）日：2013-08-08

  Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

  本文提供了化合物和前药，以及制备这些化合物和前药的方法，这些化合物和前药能够作为单胺神经递质，包括多巴胺、血清素和去甲肾上腺素的释放剂和/或摄取抑制剂发挥作用。还提供了包含这些化合物或前药中的一个或多个的药物组合物，该组合物可能进一步包含一个或多个额外的治疗药物。还提供了治疗各种可能对单胺神经递质水平修正敏感的疾病的方法，例如肥胖前期、肥胖、成瘾和抑郁症。
• Tricyclic penam compounds, their production and their use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0249909A1

  公开（公告）日：1987-12-23

  The compounds, having a 4,10-dioxo-3-oxa-7-thia-1- azatricyclo[6,2,0,02,6]decane-2-carboxylic acid skeleton as the base structure, their esters and their salts, are useful antibacterial agents.

  这些化合物以 4,10-二氧代-3-氧杂-7-硫杂-1-氮杂三环[6,2,0,02,6]癸烷-2-羧酸骨架为基础结构、 它们的酯类和盐类是有用的抗菌剂。